Onepot AI, founded by Daniil Boiko and Andrei Tyrin, has raised $13 million in a seed round led by Fifty Years, with participation from Khosla Ventures, Speedinvest, OpenAI co‑founder Wojciech Zaremba and Google chief scientist Jeff Dean. The company tackles a long‑standing bottleneck in drug discovery—chemical synthesis—by pairing a dedicated lab (POT‑1) with an AI‑driven organic chemist named Phil. Boiko and Tyrin aim to compress months‑long synthesis timelines into days, expanding the design space for biotech and pharma partners while building a second lab in San Francisco. Read more →

Nephrogen, a biotech startup founded by Stanford graduate Demetri Maxim, is developing an AI‑driven delivery system for gene‑editing medicines aimed at treating polycystic kidney disease (PKD). After a personal battle with PKD, Maxim combined insights from a 2021 Nature study with advanced screening to create a vehicle that is claimed to be 100 times more efficient than existing FDA‑approved options. The company, a finalist in TechCrunch Disrupt’s Startup Battlefield, is seeking a $4 million seed round to move its delivery platform and a companion drug into clinical trials, potentially as early as 2027. Read more →

Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years. Read more →

Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years. Read more →

Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years. Read more →

Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years. Read more →

Neuralink plans to start a new U.S. clinical trial in October that will test an implant designed to convert users' thoughts into written text. Conducted under an FDA investigational device exemption, the study aims to help individuals with speech impairments communicate directly via brain activity. The company already runs five other trials worldwide and envisions broader applications, including real‑time interaction with AI models and potential use by healthy users within a few years. Read more →

A wave of funding and rapid growth has pushed at least a dozen European startups into unicorn status this year. Companies ranging from AI coding platform Lovable in Sweden to British renewable‑energy firm Fuse Energy, streaming service Mubi, and French homomorphic‑encryption startup Zama have secured multi‑hundred‑million‑dollar rounds that lifted valuations above $1 billion. The surge spans sectors such as artificial intelligence, biotech, defense tech, space, drones, and preventative health, underscoring a broad investor appetite for high‑tech innovation across the continent. Read more →